Rucaparib vs docetaxel (DTX) or second-generation androgen receptor pathway inhibitor (ARPI) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations based on Eastern Cooperative Oncology Group performance status (ECOG PS) in TRITON3.
Por:
Reaume, MN, Fizazi, K, Bryce, AH, Chowdhury, S, Ryan, CJ, Villanueva, N, Caffo, O, Chakmakjian, CG, Ernst, DS, Feyerabend, S, Font, A, Ganju, V, Kushnir, I, Hajdenberg, J, Madsen, CV, Borrow, J, Ong, V and Ostler, PJ
Publicada:
1 mar 2026
Resumen:
Filiaciones:
Reaume, MN:
Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
Univ Ottawa, Ottawa, ON, Canada
Fizazi, K:
Univ Paris Saclay, Inst Gustave Roussy, Ctr Oscar Lambret, Lille, France
Bryce, AH:
Mayo Clin Arizona, Phoenix, AZ USA
Chowdhury, S:
Guys & St Thomas NHS Fdn Trust, London, England
Ryan, CJ:
Univ Minnesota, Minneapolis, MN USA
Villanueva, N:
Hosp Univ Cent Asturias, Oviedo, Spain
Caffo, O:
Santa Chiara Hosp, Trento, Italy
Chakmakjian, CG:
Texas Oncol, Waco, TX USA
Ernst, DS:
Western Univ, London, ON, Canada
Feyerabend, S:
Studienpraxis Urol, Nurtingen, Germany
:
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
Ganju, V:
Peninsula & South East Oncol Med, Frankston, Vic, Australia
Kushnir, I:
Tel Aviv Univ, Tel Aviv, Israel
Hajdenberg, J:
Univ Florida, Hlth Canc Ctr, Orlando, FL USA
Madsen, CV:
Univ Hosp Southern Denmark, Vejle, Denmark
Borrow, J:
Pharma, New York, NY USA
Ong, V:
Pharma, New York, NY USA
Ostler, PJ:
Mt Vernon Canc Ctr, Northwood, England
|